A Cochrane review of clinical trials evaluating psychostimulant drugs in myotonic dystrophies was published in November 2024.
Six clinical trials were selected, involving 136 participants.
- According to patient feedback, these drugs may reduce daytime sleepiness, but do not improve quality of life.
- There were discrepancies between the various trials, making the conclusions uncertain.
- In addition, the trials were only conducted on a short-term basis (less than one month) and only on adults.
New trials are needed to better assess the efficacy of these drugs.